# Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

> **NCT01113515** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novalead Pharma Private Limited** · enrollment: 44 (actual)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **DRUG:** Esmolol hydrochloride
- **DRUG:** Esmolol hydrochloride
- **DRUG:** Esmolol hydrochloride
- **DRUG:** Placebo gel

## Key facts

- **NCT ID:** NCT01113515
- **Lead sponsor:** Novalead Pharma Private Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-20
- **Primary completion:** 2015-06-27
- **Final completion:** 2015-10-17
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01113515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01113515, "Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01113515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*